We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Therapeutic Goods Act 1989
I, Jane Cook, Head, Office of Product Review, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraphs (a) and (b) below for use in advertisements directed to consumers, for the product identified in paragraph (c):
- Representations that refer to "arthritis", "osteoarthritis", "rheumatoid arthritis" and "ankylosing spondylitis" to the effect of providing accurate, balanced and contemporary educational information to consumers about the different types of arthritis;
- Representations that refer to "arthritis" and "osteoarthritis" to the effect that the product identified in paragraph (c) may provide symptomatic relief of arthritis/osteoarthritis.
- "Seatone" (AUSTL 149888)
Dated this 18 day of August 2014
Jane Cook
Delegate of the Secretary to the Department of Health; and
Head
Office of Product Review